Previous close | 964.75 |
Open | 965.90 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 954.65 - 969.65 |
52-week range | 852.00 - 1,185.25 |
Volume | |
Avg. volume | 2,322,902 |
Market cap | 779.657B |
Beta (5Y monthly) | 0.31 |
PE ratio (TTM) | 27.50 |
EPS (TTM) | 35.12 |
Earnings date | 27 July 2023 - 31 July 2023 |
Forward dividend & yield | 8.50 (0.88%) |
Ex-dividend date | 20 July 2023 |
1y target est | 1,060.63 |
Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and its wholly owned subsidiary Cipla USA Inc. (hereafter referred to as 'Cipla'), today announced the launch of Leuprolide Acetate Injection Depot 22.5mg. The product was approved by the United States Food and Drug Administration ('US FDA') based on a New Drug Application (NDA) submitted under the 505(b)(2) regulatory pathway.